Amgen, Inc.

The Maryland Prescription Drug Affordability Board (PDAB) does not automatically assume an upper payment limit is the go-to solution for drug affordability concerns, Executive Director Andrew York sai

Vigil Neuroscience’s TREM2 agonist iluzanebart failed in a Phase II study for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and deadly neurod

When clinical trial details are teased but deferred, investors will take a steer from the company management and key opinion leader commentaries. This has the potential for bias. Recent events around

Data presented in two oral sessions at the American Society of Clinical Oncology on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) and the BCMAxCD3-directed bispecific antibody linvoseltamab illustrate